GEI-BEV-2011-01 is an Observational multicenter study. The study, involving 200 (100
non-responders and 100 best responders) metastatic breast cancer patients, will search for
specific genetic variants (SNPs) and miRNA signatures associated with bevacizumab response.
Only patients suffering from metastatic (disseminated at the time of diagnosis) breast
cancer, treated with bevacizumab, will be included.
1. -To identify genetic variants as bevacizumab response predictors in metastatic breast
2. To identify miRNA signatures in whole blood as bevacizumab response predictors in
metastatic breast cancer patients.
The main endpoint will be progression-free survival (PFS)
The duration of the study will be approximately 18 months